Quick Answer
Bolt Biotherapeutics, Inc. reported Research And Development Expense of $28.53 million for the year ending 2025.
- Bolt Biotherapeutics, Inc. showed a decrease of -50.4% in Research And Development Expense from 2024 to 2025.
- This data is from Bolt Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $6.79 million | Q2 2020: $9.17 million | Q3 2020: $9.54 million | Q1 2021: $14.13 million | Q2 2021: $19.71 million | Q3 2021: $19.34 million | Q1 2022: $18.39 million | Q2 2022: $18.92 million | Q3 2022: $18.97 million | Q1 2023: $14.63 million | Q2 2023: $15.64 million | Q3 2023: $14.95 million | Q1 2024: $16.53 million | Q2 2024: $15.43 million | Q3 2024: $13.79 million | Q1 2025: $9.51 million | Q2 2025: $7.50 million | Q3 2025: $6.54 million.
- Over the full 6 years of available data (2020 to 2025), Bolt Biotherapeutics, Inc.'s Research And Development Expense has declined by 29.3%.
- Historical annual values: Fiscal year 2025: $28.53 million | Fiscal year 2024: $57.47 million | Fiscal year 2023: $61.54 million | Fiscal year 2022: $73.12 million | Fiscal year 2021: $75.66 million | Fiscal year 2020: $40.36 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: